ATE469129T1 - N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide - Google Patents

N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide

Info

Publication number
ATE469129T1
ATE469129T1 AT06014422T AT06014422T ATE469129T1 AT E469129 T1 ATE469129 T1 AT E469129T1 AT 06014422 T AT06014422 T AT 06014422T AT 06014422 T AT06014422 T AT 06014422T AT E469129 T1 ATE469129 T1 AT E469129T1
Authority
AT
Austria
Prior art keywords
optionally substituted
alkyl
alk
halo
nalk
Prior art date
Application number
AT06014422T
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Serge Martinez
Philippe Pointeau
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE469129T1 publication Critical patent/ATE469129T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
AT06014422T 2006-07-11 2006-07-11 N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide ATE469129T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06014422A EP1878723B1 (de) 2006-07-11 2006-07-11 N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamid-Derivate Antagonisten der CB1 Rezeptoren der Cannabinoide

Publications (1)

Publication Number Publication Date
ATE469129T1 true ATE469129T1 (de) 2010-06-15

Family

ID=37488039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06014422T ATE469129T1 (de) 2006-07-11 2006-07-11 N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide

Country Status (3)

Country Link
EP (1) EP1878723B1 (de)
AT (1) ATE469129T1 (de)
DE (1) DE602006014532D1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
GB201103419D0 (de) 2011-02-28 2011-04-13 Univ Aberdeen
WO2012174362A1 (en) * 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
FR2864958B1 (fr) * 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
EP1878723A1 (de) 2008-01-16
DE602006014532D1 (de) 2010-07-08
EP1878723B1 (de) 2010-05-26

Similar Documents

Publication Publication Date Title
CA2772718C (en) Compounds as tyrosine kinase modulators
CN106986857B (zh) Trk抑制化合物
RU2437877C2 (ru) Новые производные тиофена в качестве агонистов рецептора s1p1/edg1
CN101952254B (zh) Atp结合盒转运蛋白的异喹啉调节剂
DE60203263T2 (de) Pyrazolderivate gegen tgf überexprimierung
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BR0017025A (pt) Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda
NO20071193L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
JP2015131860A (ja) Ｃｆｔｒモジュレーターとしてのピリジル誘導体
JP2003535887A5 (de)
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
JP2007039461A5 (de)
RU2008152180A (ru) ПРОИЗВОДНЫЕ ПИРРОЛА, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ CRTh2 РЕЦЕПТОРА
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
ATE469129T1 (de) N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
RU2012143897A (ru) Замещенные пиримидины как антагонисты рецепторов простагландина d2
NO20060191L (no) 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)2,2-difenylacetamidderivater som muskarinreceptoragonister
JP2005500286A5 (de)
JP2005503433A5 (de)
JP2007527424A5 (de)
Chambers et al. 3-(Piperazinylpropyl) indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents
JP2006503857A5 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties